Truist Securities raises Exelixis stock price target to $56 on positive outlook

Exelixis (EXEL) has seen multiple analyst price target upgrades, including Truist Securities raising its target to $56, driven by strong financial health, impressive gross profit margins, and promising drug developments. The company's cancer drug Cabometyx is showing robust performance, and its next-generation drug Zanza is projected for a 2026 launch with a clear path to $5 billion in revenue. Most notably, positive top-line results from the STELLAR-303 Phase 3 trial for zanzalintinib in metastatic colorectal cancer have significantly bolstered analyst confidence, leading to higher approval probability estimates and substantial commercial opportunity, positioning EXEL for continued growth despite some lingering concerns about valuation and pipeline diversification.

Analysis

Exelixis (EXEL) is experiencing a significant positive catalyst following top-line results from its STELLAR-303 Phase 3 trial, which demonstrated a notable overall survival benefit for its zanzalintinib combination therapy in metastatic colorectal cancer. This clinical success has prompted multiple analysts to re-evaluate the company's outlook, with H.C. Wainwright raising its price target to $53 and increasing the drug's approval probability to 80%, while Truist lifted its target to $56. The trial's positive outcome materially de-risks the 2026 launch of the next-generation drug, Zanza (zanzalintinib), which Truist projects has a clear path to $5 billion in revenue from six indications. This pipeline development is supported by the sustained performance of the company's legacy cancer drug, Cabometyx, which continues to exhibit robust growth. Exelixis's financial health is exceptionally strong, evidenced by a 96.78% gross profit margin and a perfect Piotroski Score of 9. However, a degree of caution persists; UBS maintains a Neutral rating with a $38 target due to pipeline diversification concerns, and Stifel's surprise at the trial outcome highlights that this level of success was not universally anticipated. Despite the stock's 102% gain over the past year and attendant valuation concerns, the recent clinical and analyst momentum suggests a strong fundamental underpinning for further growth.

Key Decisions for Investors

• The positive Phase 3 data for zanzalintinib significantly de-risks a major future revenue driver, supporting the bullish analyst cases and suggesting that the stock's growth trajectory may be sustainable.
• Investors should weigh the recent 102% share price appreciation and existing valuation concerns against the new, tangible clinical progress that may not be fully priced in, as indicated by some analysts' surprise at the trial's success.
• Monitor progress on Zanza's five other indications, as pipeline diversification remains a key concern highlighted by neutral-rated analysts like UBS, and long-term value will depend on success beyond a single indication.
• Note the divergence in analyst ratings; while multiple firms raised targets, the cautious stances from UBS and Stifel present a risk factor to consider, but also an opportunity if the market has not yet reached a full consensus on the trial's impact.